Related Experiment Videos
Intracellular Cytokines Produced by Stimulated CD3+ Cells from Chronic Myeloid Leukemia Patients
Pavlina Ptackova1, Martina Petrackova, Miroslav Hindos
1Department of Immunology, Institute of Hematology and Blood Transfusion, General University Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic.
Insights
Cytokine production by CD3+ cells is suppressed in chronic myeloid leukemia (CML) patients at diagnosis. Treatment leading to remission significantly restores interferon-gamma (IFN-γ) and other cytokine levels, indicating immune recovery.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome.
- Immune dysregulation is increasingly recognized in CML pathogenesis and progression.
- The role of T-cell cytokine production in CML remains incompletely understood.
Purpose of the Study:
- To investigate the production of key cytokines by CD3+ cells in CML patients.
- To assess the impact of tyrosine-kinase inhibitor (TKI) therapy on T-cell cytokine profiles.
- To explore correlations between cytokine production, clinical parameters, and treatment outcomes in CML.
Main Methods:
- Intracellular cytokine production (interferon-gamma, tumor necrosis factor-alpha, interleukin-2, and -4) was measured in vitro stimulated CD3+ cells from 38 CML patients and healthy controls.
- Flow cytometry was used to quantify cytokine-producing cells.
- Statistical analyses were performed to compare patient groups and assess correlations.
Main Results:
- At diagnosis, CML patients showed significantly suppressed production of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2) compared to controls.
- Successful treatment with TKIs leading to hematological remission was associated with a significant increase in the production of all four measured cytokines.
- Higher percentages of cytokine-producing CD3+ cells at diagnosis were linked to optimal therapy outcomes, particularly for IFN-γ and IL-2.
Conclusions:
- T-cell cytokine production is impaired in newly diagnosed CML patients.
- TKI therapy effectively restores T-cell immune function, as evidenced by increased cytokine production during remission.
- Pre-treatment levels of cytokine-producing CD3+ cells may serve as a predictive marker for CML treatment response.
Abstract:
Our work examined the production of intracellular interferon (INF)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-2, and IL-4 by in vitro stimulated CD3+ cells from 38 chronic myeloid leukemia (CML) patients. At the time of diagnosis the percentages of cells producing INF-γ, TNF-α, and IL-2 were strongly suppressed compared to those in healthy control subjects. Hematological remission achieved through treatment with tyrosine-kinase inhibitors was associated with a highly significant increase in the ratio of cells producing all 4 cytokines. The percentages of CD3+ cells producing cytokines were dependent on age, more so in CML patients than in healthy controls, and they negatively correlated with the number of leukocytes. Patients with an optimal therapy outcome possessed higher percentages of cytokine-producing CD3+ cells at diagnosis than those with nonoptimal outcomes. This difference was statistically significant in the case of INF-γ-producing cells, and it was on the brink of significance in the case of IL-2-producing cells.